Data highlight progress toward personalized stem cell therapy for Parkinson's disease

by International Society for Stem Cell Research

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

Interim clinical findings from the first Phase I/IIa trial using autologous-induced pluripotent stem cell (iPSC)-derived dopamine neuron precursor cells, along with the novel quality-control tools developed to manufacture these individualized therapies, have been presented by Jeanne Loring, Ph.D., Scripps Research, U.S., at the ISSCR 2026 Annual Meeting.

Parkinson's disease is a progressive neurological disorder caused by the gradual loss of dopamine-producing nerve cells in the brain. As dopamine levels decline, people develop symptoms such as tremor, stiffness, slowed movement and balance problems. While current medications can temporarily improve symptoms, they do not stop the disease from progressing or replace the neurons that have been lost.

Screening each patient's cells

The study uses an approach in which dopamine neuron precursor cells are generated from each patient's own cells. Because every patient's cells are unique, the team developed new genomic quality-control methods to ensure the manufactured cells are suitable for transplantation.

Using whole-genome sequencing throughout the manufacturing process, the researchers established a "fail-fast" strategy designed to identify unwanted genetic changes that can arise as iPSCs are expanded and differentiated.

The presentation will describe these quality-control tools for autologous manufacturing, together with positive interim findings from patients one year after receiving transplants of their own cells.

"The greatest challenge for autologous cell therapy has been developing reliable methods to qualify every patient's cells for treatment," said Loring. "We developed genomic analysis approaches that address cell-line heterogeneity and identify mutations that can arise as iPSCs divide, helping establish a rigorous framework for manufacturing personalized therapies."

Early signals after transplantation

The trial addresses an important unmet need for people with sporadic Parkinson's disease. While several clinical studies are evaluating stem cell-derived dopamine neurons, this is the first Phase I/IIa trial using autologous iPSC-derived dopamine neuron precursors transplanted into the region of the brain where dopamine neuron input has been lost.

Interim results have been reported for eight patients with mild to moderate Parkinson's disease who remained responsive to L-DOPA treatment and were evaluated 12 months after transplantation.

"We've known for decades that transplanted young dopamine neurons can reverse Parkinson's disease symptoms when the appropriate cells are used," said Loring. "If these findings continue to hold over time, we hope to see meaningful improvements in quality of life that continue to increase as the transplanted cells mature."

While the results provide important proof of concept for the approach, Loring noted that additional questions remain, including determining the optimal therapeutic dose.

"I believe these findings are an important milestone because they provide proof of concept for both the safety and potential efficacy of personalized stem cell therapy," she said. "I'm excited to share these data with the ISSCR community and discuss how far the field has advanced toward translating autologous iPSC technology into clinical therapies."

Key medical concepts

Parkinson's DiseaseCell Transplantation

Clinical categories

Neurology Provided by International Society for Stem Cell Research Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Data highlight progress toward personalized stem cell therapy for Parkinson's disease (2026, July 9) retrieved 9 July 2026 from https://medicalxpress.com/news/2026-07-highlight-personalized-stem-cell-therapy.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.